According to the American Migraine Foundation, migraine affects 1 in 4 households in the US, and over 1 billion people worldwide live with migraine.
While there is no cure for migraine, pharmaceutical companies continue to innovate to provide treatment options for patients suffering from migraine.
It is an exciting time for migraine treatment.
Since 2018, ten new products have become available for migraine treatment. New therapies include new classes of drugs, such as calcitonin gene-related peptide (CGRP) monoclonal antibodies and CGRP-targeting gepants.
Related Insights & Outlooks
Novel and Emerging Treatments in Spinal Muscular Atrophy
Atacana Group
•
June 1, 2023
Marketed products are being evaluated for age expansion, dose increase, and in previously treated SMA patients
Antiviral Vaccines 2024 & 2025 Catalysts Report
Atacana Group
•
April 19, 2024
The Leading companies in the Antiviral Vaccine market, such as Pfizer, Moderna, GSK, and AstraZeneca are anticipating pivotal advancements, including regulatory milestones, clinical trial updates, and strategic product launches.
.avif)